Skip to content

Emotional body odors alter autonomic nervous activity during mindfulness training in social anxiety.

Elisa Dal Bò, Cinzia Cecchetto, Letizia Zurlo, L. Lavezzo, Emma T Eliasson, Elisa Vigna, E. P. Scilingo, A. Greco, Mimma Nardelli, Fabio Di Francesco, Gergö Hadlaczky, J. Lundström, V. Carli, Claudio Gentili

Journal of Anxiety Disorders June 10, 2026 DOI: 10.1016/j.janxdis.2026.103201 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 98
Population Women with social anxiety
Interventions Mindfulness sessions clean air
Duration Two mindfulness sessions over two consecutive days
Measures Heart rate variability (HRV), electrodermal activity (EDA)
Topics Anxiety Meditation
Key findings Fear and happiness body odors, but not neutral body odor or clean air, were associated with reduced heart rate variability during mindfulness practice. Baseline heart rate variability predicted greater anxiety reduction only in the fear body odor group. The authors propose that emotional body odors, particularly fear odor, may enhance mindfulness efficacy by providing a socially salient, ecologically valid context that trains adaptive regulation.

Abstract

Chemosignals found in human body odors (BOs) convey information about a person's emotional state and elicit observable responses in others. While mindfulness typically enhances parasympathetic tone and reduces anxiety, little is known about how BOs modulate these effects. This study investigated how emotional and non-emotional human BOs influence autonomic nervous system activity - heart rate variability (HRV) and electrodermal activity (EDA) - during mindfulness practice in individuals with social anxiety. The role of baseline HRV as a predictor of intervention outcome was explored. Ninety-eight women with social anxiety received two mindfulness sessions over two consecutive days, while allocated to one of four conditions: fear BO, happiness BO, neutral BO, clean air. Due to technical issues, final samples were reduced (n = 69-85 per analysis). Individuals in the fear and happiness BOs conditions, but not those in the neutral BO and clean air conditions, showed HRV reduction during the mindfulness. EDA decreased in all conditions on day 1, but on day 2, only the clean air and neutral BO groups maintained this reduction. Baseline HRV predicted the magnitude of anxiety reduction in the fear BO group; participants with higher initial HRV exhibited greater anxiety reduction. No associations were found for other odor conditions. These results suggest that emotional BOs, particularly fear BO, may enhance mindfulness efficacy by creating a socially salient and ecologically valid context. For socially anxious individuals, practicing mindfulness under a subtle social-emotional challenge may train adaptive regulation. Baseline HRV emerges as a biomarker of such regulatory flexibility and intervention responsiveness.

Comparable studies

Other randomized controlled trials on anxiety, most cited first.

Study Year Design Participants
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Hallucinogen-naïve adults reporting regular participation in religious or spiritual... 2006 Double-blind study n = 36
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Adults with advanced-stage cancer and anxiety 2010 Double-blind, placebo-controlled study n = 12

Citations in the library

Explore topics